GLP-1 Multidistrict Litigation Status 2025 As of 2025, hundreds of Ozempic lawsuits filed against Novo Nordisk have been consolidated into multidistrict litigation (MDL) in the Eastern District of Pennsylvania
These may include allergic reactions to unknown ingredients, lack of therapeutic effect (meaning underlying conditions remain untreated), contamination with harmful substances, or unpredictable side effects
Knowing the facts can help you make safer and smarter health decisions
The UK GLP-1 programme offers virtual workshops and community support through the app and Connect platform
Genetic Predispositions and Metabolic Response to Weight Management Strategies The PlexusDx Precision Peptide Genetic Test analyzes GLP1R, GIPR, FTO, and MC4R variants that relate to GLP-1 and related signaling pathways
Some patches are marketed as boosting GLP-1 levels